InVivoSIM anti-human PD-1 (Sintilimab Biosimilar)

Catalog #SIM0054
Clone:
Sintilimab
Reactivities:
Human, Monkey

$235.00 - $8,140.00

$235.00 - $8,140.00

Choose an Option...
  • 100 mg - $8,140.00
  • 50 mg - $4,574.00
  • 25 mg - $3,182.00
  • 5 mg - $911.00
  • 1 mg - $235.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Details

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, Sintilimab, making it ideal for research use. Sintilimab is a humanized IgG4 kappa monoclonal antibody with an S228P hinge stabilization mutation that specifically reacts with programmed cell death protein 1 (PD-1), also known as CD279. Sintilimab is shown to have a greater affinity for human PD-1 compared to both nivolumab and pembrolizumab. Sintilimab also shows cross-reactivity to PD-1 cynomolgus monkey species. PD-1 is an inhibitory receptor belonging to the CD28 family of the Ig superfamily, and it is transiently expressed on the cell surface of CD4 and CD8 T cells, B cells, as well as myeloid cells. PD-L1 is the main ligand of PD-1 and is expressed on the surface of tumor cells and antigen-presenting cells (APCs). PD-1 and PD-L1 interactions are central to immune homeostasis and prevention of autoimmunity. PD-1 binding to PD-L1 inhibits T cell activation, thereby diminishing T cell proliferation, cytokine production, and cytotoxic activity. This phenomenon is critical in the downregulation of the immune response during chronic inflammation and minimizing tissue damage. Cancers, such as squamous cell carcinoma, lung cancer, melanoma, ovarian cancer, renal cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma, often express PD-L1 in high abundance, wherein the cancer cells exploit the PD1/PD-L1 pathway to evade immune surveillance via immune evasion. In immune checkpoint inhibitor-responsive experimental models, the tumor growth can be transiently arrested in vivo through treatment with anti-PD-1 antibodies, e.g., sintilimab, which block the interactions between PD-1 and PD-L1 proteins.

Specifications

Isotype Human IgG4, Īŗ
Recommended Isotype Control(s) RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Mutations S228P
Immunogen Human PD-1
Reported Applications in vivo functional assays
in vitro functional assays
Flow cytometry
ELISA
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <0.5EU/mg (<0.0005EU/μg)
Determined by LAL gel clotting assay
Aggregation <5%
Determined by SEC
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein A
Molecular Weight 150 kDa
Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.